Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

NCT ID: NCT04378543

Last Updated: 2020-10-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-30
• Study Completion Date: 2023-10-31

Brief Summary

Ankasa Regenerative Therapeutics, Inc. (Ankasa) is developing ART352-L, a liposomal formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested autologous bone grafts (autograft) to enhance the osteogenic properties of the autograft prior to reimplantation in orthopedic surgeries.

This is a phase 1/2 open label safety evaluation of ART352-L treated autologous bone grafts in patients undergoing posterolateral lumbar spinal fusion to treat single level degenerative spondylolisthesis. The primary objective of the study is to evaluate the safety and tolerability of ART352-L treated local bone autografts in patients being treated for this condition, with the secondary objective to evaluate the rates of early and overall spinal fusion. Additionally, changes in patient mobility and quality of life measures from baseline following treatment with ART352-L will be evaluated.

Conditions

Degenerative Spondylolisthesis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ART252-L

local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion

Group Type: EXPERIMENTAL

ART352-L

Intervention Type: BIOLOGICAL

recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures

Interventions

ART352-L

recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects ≥50 years of age scheduled to undergo single level posterolateral lumbar spinal fusion surgery in conjunction with local autograft bone for degenerative spondylolisthesis

2. Psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent

3. Willing and able to undergo diagnostic imaging, inclusive of X-rays and CT scans with contrast

4. Persistent, disabling pain after at least 6 months of non-surgical intervention (e.g., anti-inflammatory medication, physical therapy, chiropractic care) prior to providing informed consent

5. Pre-operative Oswestry Disability Index (ODI) Score ≥30

6. Grade 1 or less spondylolisthesis or retrolisthesis

7. Absence of neurological motor deficit

8. Agree to use a highly reliable method of birth control (male and female subjects) for at least 90 days after administration of Investigational Product (IP) - Women of childbearing potential must have a negative pregnancy test at screening and again ≤7 days prior to surgery. Perimenopausal women must be amenorrheic for at least 12 months prior to the time of providing informed consent to be considered of non-childbearing potential.

9. Agree to remain nicotine-free for the duration of their participation in the study

Exclusion Criteria

1. Multiple level spondylolistheses or a primary diagnosis of low back pain syndrome secondary to diseases other than degenerative spondylolisthesis

2. Concurrent medications that affect bone homeostasis including, but not limited to, bisphosphonates

3. Ongoing / existing infections in or around the surgical site or spine

4. Prior lumbar spine arthrodesis

5. Concurrent clinically significant autoimmune disorder or systemic inflammatory disease

6. Known hypersensitivity to recombinant Wnt proteins

7. Use of tobacco; subjects must be nicotine-free at screening and agree to remain nicotine free for the duration of the study

8. Use of medications that may impair cell proliferation and bone healing including: chemotherapy, radiation, chronic steroids and immunosuppressive drugs. Note: Medications that may impair cell proliferation are to be discussed with the protocol medical monitor prior to enrollment

9. Severe established osteoporosis requiring active treatment e.g., with bone density more than 2.5 standard deviations below the young adult mean with one or more osteoporotic fractures

10. A Body Mass index (BMI) ≥ 40 unless documentation clearly demonstrates why BMI is not a primary factor in the subject's decreased mobility

11. Chronic opioid use

12. History of deep vein thrombosis (DVT) or blood clotting abnormalities

13. Uncontrolled diabetes mellitus

14. Pre-operative/anesthesia evaluations deeming the subject ineligible for surgery

15. Female subjects who are pregnant or intend to become pregnant during the course of the study

16. Male subjects, if not infertile or surgically sterilized, who will not agree to use highly-effective contraception or to not donate sperm from screening until at least 90 days after receiving IP

17. Active malignancy ≤5 years prior to providing informed consent. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, the subject must not be receiving other specific treatment for their cancer.

18. Concurrent participation in another investigational drug, biologic or device study that could confound study data

19. Involvement in or plans to engage in litigation or receiving Worker's Compensation related to neck, back, or leg pain

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ankasa Regenerative Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Keck School of Medicine, University of Southern California

Los Angeles, California, United States

Site Status: RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status: RECRUITING

Wexner Medical Center, The Ohio State University

Columbus, Ohio, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Gloria Matthews, DVM, PhD

Role: CONTACT

gmatthews@wnt3.com

404-947-6472

Sanford Madigan, PhD

Role: CONTACT

smadigan@wnt3.com

Facility Contacts

Jeffrey Wang, MD

Role: primary

Brett Freedman, MD

Role: primary

Safdar Khan, MD

Role: primary

Other Identifiers

ART-SPF-ART352L-001

Identifier Type: -

Identifier Source: org_study_id